Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2013

01-12-2013 | Article

HIV-1 coreceptor switch during 2 years of structured treatment interruptions

Authors: S. Baroncelli, C. M. Galluzzo, M. Andreotti, M. F. Pirillo, V. Fragola, L. E. Weimer, M. Giuliano, S. Vella, L. Palmisano

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2013

Login to get access

Abstract

The purpose of this investigation was to determine the impact on human immunodeficiency virus (HIV) tropism of uncontrolled virus exposure during 2 years of intermittent highly active antiretroviral therapy (HAART). The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) randomized study compared the outcome of 2 years of structured treatment interruptions (STIs) versus standard continuous treatment in first-line HAART responder subjects. The STI schedule consisted of five STIs of 1, 1, 2, 2, and 3 months, respectively, separated by four periods of 3-month therapy. In the present study, coreceptor tropism was assessed in 12 patients of the STI arm at different time points over a period of 2 years. Tropism was determined on DNA and RNA by V3 loop region sequencing. The Geno2pheno algorithm (false-positive rate, FPR: 20 %) was used for data interpretation. At baseline, 9/12 subjects (75.0 %) had CCR5-tropic viruses in their HIV. Three had a CXCR4-tropic virus. Ten patients maintained the same coreceptor in DNA after 2 years, whereas in two patients, a shift occurred (one R5–X4, one X4–R5). In a patient with an R5 virus at baseline, a transient change to X4 tropism was seen in the rebounding virus during STI. Changes in tropism were not associated with the amplitude and duration of virus exposure during STIs, residual viremia at baseline, or the development of resistance mutations in the RT region. Our preliminary results suggest that viral replication, observed after short periods of treatment interruption, is not enough to drive the evolution of HIV tropism.
Literature
1.
go back to reference Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G (2008) The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46(10):1617–1623PubMedCrossRef Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G (2008) The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46(10):1617–1623PubMedCrossRef
2.
go back to reference Verhofstede C, Nijhuis M, Vandekerckhove L (2012) Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS 7(5):432–439PubMedCrossRef Verhofstede C, Nijhuis M, Vandekerckhove L (2012) Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS 7(5):432–439PubMedCrossRef
3.
go back to reference Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte AdA, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers (2007) Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 46(1):39–47PubMed Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte AdA, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers (2007) Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 46(1):39–47PubMed
4.
go back to reference Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study (2003) Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol 77(24):13146–13155PubMedCrossRef Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study (2003) Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol 77(24):13146–13155PubMedCrossRef
5.
go back to reference Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S (2005) Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 19(16):1843–1847PubMedCrossRef Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S (2005) Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 19(16):1843–1847PubMedCrossRef
7.
go back to reference Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M (2012) Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. J Antimicrob Chemother 67(6):1479–1485PubMedCrossRef Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M (2012) Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. J Antimicrob Chemother 67(6):1479–1485PubMedCrossRef
8.
go back to reference Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing (2011) European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11(5):394–407PubMedCrossRef Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing (2011) European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11(5):394–407PubMedCrossRef
9.
go back to reference Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K, Cuzin L, Marchou B, Massip P, Izopet J (2008) Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22(14):F11–F16PubMedCrossRef Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K, Cuzin L, Marchou B, Massip P, Izopet J (2008) Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22(14):F11–F16PubMedCrossRef
10.
go back to reference Delobel P, Sandres-Sauné K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J (2005) R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38(4):382–392PubMedCrossRef Delobel P, Sandres-Sauné K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J (2005) R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38(4):382–392PubMedCrossRef
11.
go back to reference Seclén E, Del Mar González M, De Mendoza C, Soriano V, Poveda E (2010) Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 65(7):1493–1496 Seclén E, Del Mar González M, De Mendoza C, Soriano V, Poveda E (2010) Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 65(7):1493–1496
12.
go back to reference Waters LJ, Scourfield AT, Marcano M, Gazzard BG, Bower M, Nelson M, Stebbing J (2011) The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin Infect Dis 52(5):671–673PubMedCrossRef Waters LJ, Scourfield AT, Marcano M, Gazzard BG, Bower M, Nelson M, Stebbing J (2011) The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin Infect Dis 52(5):671–673PubMedCrossRef
13.
go back to reference Wirden M, Soulié C, Fourati S, Valantin MA, Simon A, Ktorza N, Tubiana R, Bonmarchand M, Schneider L, Calvez V, Katlama C, Marcelin AG (2013) Pitfalls of HIV genotypic tropism testing after treatment interruption. J Antimicrob Chemother 68(1):188–189PubMedCrossRef Wirden M, Soulié C, Fourati S, Valantin MA, Simon A, Ktorza N, Tubiana R, Bonmarchand M, Schneider L, Calvez V, Katlama C, Marcelin AG (2013) Pitfalls of HIV genotypic tropism testing after treatment interruption. J Antimicrob Chemother 68(1):188–189PubMedCrossRef
14.
go back to reference Sarmati L, Parisi SG, Andreoni C, Nicastri E, Buonomini AR, Boldrin C, Dori L, Montano M, Tommasi C, Andreis S, Vullo V, Palù G, Andreoni M (2010) Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy. J Clin Microbiol 48(7):2586–2588PubMedCrossRef Sarmati L, Parisi SG, Andreoni C, Nicastri E, Buonomini AR, Boldrin C, Dori L, Montano M, Tommasi C, Andreis S, Vullo V, Palù G, Andreoni M (2010) Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy. J Clin Microbiol 48(7):2586–2588PubMedCrossRef
15.
go back to reference de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V; Spanish HIV Seroconverter Study Group (2008) Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J Acquir Immune Defic Syndr 48(3):241–4PubMedCrossRef de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V; Spanish HIV Seroconverter Study Group (2008) Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J Acquir Immune Defic Syndr 48(3):241–4PubMedCrossRef
16.
go back to reference Sucupira MC, Sanabani S, Cortes RM, Giret MT, Tomiyama H, Sauer MM, Sabino EC, Janini LM, Kallas EG, Diaz RS (2012) Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One 7(1):e30292PubMedCrossRef Sucupira MC, Sanabani S, Cortes RM, Giret MT, Tomiyama H, Sauer MM, Sabino EC, Janini LM, Kallas EG, Diaz RS (2012) Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One 7(1):e30292PubMedCrossRef
17.
go back to reference Equils O, Garratty E, Wei LS, Plaeger S, Tapia M, Deville J, Krogstad P, Sim MS, Nielsen K, Bryson YJ (2000) Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J Infect Dis 182(3):751–757PubMedCrossRef Equils O, Garratty E, Wei LS, Plaeger S, Tapia M, Deville J, Krogstad P, Sim MS, Nielsen K, Bryson YJ (2000) Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J Infect Dis 182(3):751–757PubMedCrossRef
18.
go back to reference Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA 3rd, Sacks HS, Mathur-Wagh U, Brunner C, Burger H (2001) Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 107(4):431–438PubMedCrossRef Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA 3rd, Sacks HS, Mathur-Wagh U, Brunner C, Burger H (2001) Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 107(4):431–438PubMedCrossRef
19.
go back to reference Andrianov AM, Kornoushenko YV, Anishchenko IV, Eremin VF, Tuzikov AV (2012) Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe. J Biomol Struct Dyn. Aug 13 [Epub ahead of print] PubMed PMID: 22888999 Andrianov AM, Kornoushenko YV, Anishchenko IV, Eremin VF, Tuzikov AV (2012) Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe. J Biomol Struct Dyn. Aug 13 [Epub ahead of print] PubMed PMID: 22888999
20.
go back to reference Soulie C, Lambert-Niclot S, Wirden M, Simon A, Valantin MA, Fourati S, Tubiana R, Katlama C, Calvez V, Marcelin AG (2011) Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. AIDS 25(4):537–539PubMedCrossRef Soulie C, Lambert-Niclot S, Wirden M, Simon A, Valantin MA, Fourati S, Tubiana R, Katlama C, Calvez V, Marcelin AG (2011) Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. AIDS 25(4):537–539PubMedCrossRef
21.
go back to reference Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G (2009) Co-receptor switch during HAART is independent of virological success. J Med Virol 81(12):2036–2044PubMedCrossRef Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G (2009) Co-receptor switch during HAART is independent of virological success. J Med Virol 81(12):2036–2044PubMedCrossRef
Metadata
Title
HIV-1 coreceptor switch during 2 years of structured treatment interruptions
Authors
S. Baroncelli
C. M. Galluzzo
M. Andreotti
M. F. Pirillo
V. Fragola
L. E. Weimer
M. Giuliano
S. Vella
L. Palmisano
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2013
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-013-1911-z

Other articles of this Issue 12/2013

European Journal of Clinical Microbiology & Infectious Diseases 12/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine